Cabio Biotech (Wuhan) Co., Ltd.

SHSE:688089 Voorraadrapport

Marktkapitalisatie: CN¥3.4b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Cabio Biotech (Wuhan) Toekomstige groei

Future criteriumcontroles 2/6

Cabio Biotech (Wuhan) is forecast to grow earnings and revenue by 15.2% and 15.4% per annum respectively. EPS is expected to grow by 15.8% per annum. Return on equity is forecast to be 9.4% in 3 years.

Belangrijke informatie

15.2%

Groei van de winst

15.8%

Groei van de winst per aandeel

Chemicals winstgroei33.7%
Inkomstengroei15.4%
Toekomstig rendement op eigen vermogen9.4%
Dekking van analisten

Low

Laatst bijgewerkt29 Aug 2024

Recente toekomstige groei-updates

Recent updates

Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

Oct 01
Subdued Growth No Barrier To Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) With Shares Advancing 31%

There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Aug 06
There's Reason For Concern Over Cabio Biotech (Wuhan) Co., Ltd.'s (SHSE:688089) Massive 25% Price Jump

Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Jun 07
Cabio Biotech (Wuhan) (SHSE:688089) Could Be Struggling To Allocate Capital

Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

May 06
Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

May 03
Cabio Biotech (Wuhan)'s (SHSE:688089) Promising Earnings May Rest On Soft Foundations

The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Mar 21
The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Winst- en omzetgroeiprognoses

SHSE:688089 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026711179N/A1771
12/31/2025659147N/A1483
12/31/2024535117N/A1283
6/30/2024506124-84173N/A
3/31/2024473101-169118N/A
12/31/202344491-22969N/A
9/30/202348547-178118N/A
6/30/202346149-150106N/A
3/31/202344655-126107N/A
12/31/202243364-73176N/A
9/30/2022374105-104133N/A
6/30/2022359111-96153N/A
3/31/2022348118-66177N/A
12/31/2021351129-70103N/A
9/30/2021337121-3484N/A
6/30/20213361272498N/A
3/31/20213471393678N/A
12/31/2020323131113146N/A
9/30/2020317132152174N/A
6/30/2020315126147161N/A
3/31/2020301121145165N/A
12/31/2019312118109132N/A
9/30/201931812889119N/A
12/31/20182869794106N/A
12/31/201722966N/A101N/A
12/31/201619047N/A63N/A
12/31/201518120N/A45N/A
12/31/201418738N/A46N/A
12/31/201320047N/A39N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 688089's forecast earnings growth (15.2% per year) is above the savings rate (2.9%).

Winst versus markt: 688089's earnings (15.2% per year) are forecast to grow slower than the CN market (23.2% per year).

Hoge groeiwinsten: 688089's earnings are forecast to grow, but not significantly.

Omzet versus markt: 688089's revenue (15.4% per year) is forecast to grow faster than the CN market (13.2% per year).

Hoge groei-inkomsten: 688089's revenue (15.4% per year) is forecast to grow slower than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: 688089's Return on Equity is forecast to be low in 3 years time (9.4%).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y